Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.
30.10.2025 11:32
Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
30.10.2025 10:30
RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
Best Dividend Kings: October 2025
29.10.2025 05:11
Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Read more here.
Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results
29.10.2025 01:42
Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Freedom Capital Markets has lowered its rating on Johnson & Johnson (NYSE:JNJ) from Buy to Hold, even as it raised the stock’s price target from $180 to $190 following a solid third-quarter performance. The healthcare company […]
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
27.10.2025 16:45
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
3 Healthcare Stocks to Buy Hand Over Fist in October
27.10.2025 14:45
One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
27.10.2025 13:50
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
27.10.2025 13:19
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial
27.10.2025 12:26
Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga
Johnson and Johnson to spin off orthopaedics market
27.10.2025 12:24
The company announced a formal plan to explore strategic alternatives for the segment, which has resulted in the spin-off.
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
27.10.2025 12:00
Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety.
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
27.10.2025 11:30
Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
27.10.2025 11:30
Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted a
Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal
27.10.2025 09:26
Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash.
3 Healthcare Stocks Paying the Highest Dividends of 2025
27.10.2025 08:30
If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
23.10.2025 14:01
Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.
AngioInsight Appoints Medtech Veteran Shlomi Nachman to Board of Directors; Announces Series A Round to Accelerate AI-Driven Advancement in Cardiology
23.10.2025 12:00
MINNETONKA, Minn., October 23, 2025--AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed seed funding round. The investment will support the ongoing development of AngioAI+™, the com
GCC $1.25+ Bn Catheter Market Growth Trends and Forecast to 2033 Featuring Abbott, Edwards Lifesciences, BD and Co, Boston Scientific, Medtronic, Johnson & Johnson, Stryker, Teleflex
23.10.2025 09:09
The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow